Phreesia (NYSE:PHR) Stock Price Down 4.2%

Phreesia, Inc. (NYSE:PHR) shares fell 4.2% during mid-day trading on Thursday . The stock traded as low as $23.03 and last traded at $23.15. 183,188 shares changed hands during trading, a decline of 60% from the average session volume of 462,161 shares. The stock had previously closed at $24.17.

Wall Street Analyst Weigh In

Several analysts have commented on PHR shares. DA Davidson reaffirmed a “buy” rating and issued a $32.00 target price on shares of Phreesia in a research note on Thursday. Needham & Company LLC reiterated a “buy” rating and set a $29.00 target price on shares of Phreesia in a research report on Thursday. Stephens reissued an “overweight” rating and issued a $28.00 price target on shares of Phreesia in a research note on Friday, May 31st. Truist Financial upped their price objective on shares of Phreesia from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Friday. Finally, Robert W. Baird raised their target price on shares of Phreesia from $31.00 to $34.00 and gave the stock an “outperform” rating in a research report on Friday. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, Phreesia has an average rating of “Moderate Buy” and a consensus target price of $30.92.

Phreesia Trading Down 8.3 %

The firm’s 50 day simple moving average is $23.38 and its 200-day simple moving average is $22.79. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.35 billion, a PE ratio of -10.85 and a beta of 0.93.

Insider Buying and Selling

In other Phreesia news, General Counsel Allison C. Hoffman sold 14,110 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $26.03, for a total transaction of $367,283.30. Following the transaction, the general counsel now owns 121,003 shares in the company, valued at $3,149,708.09. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, SVP David Linetsky sold 1,820 shares of the firm’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $23.74, for a total transaction of $43,206.80. Following the completion of the sale, the senior vice president now directly owns 202,218 shares of the company’s stock, valued at approximately $4,800,655.32. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel Allison C. Hoffman sold 14,110 shares of Phreesia stock in a transaction on Monday, August 26th. The stock was sold at an average price of $26.03, for a total transaction of $367,283.30. Following the sale, the general counsel now directly owns 121,003 shares in the company, valued at approximately $3,149,708.09. The disclosure for this sale can be found here. In the last three months, insiders sold 29,337 shares of company stock valued at $736,750. Company insiders own 5.80% of the company’s stock.

Institutional Trading of Phreesia

Large investors have recently modified their holdings of the business. New York State Common Retirement Fund boosted its holdings in Phreesia by 13.0% in the fourth quarter. New York State Common Retirement Fund now owns 53,865 shares of the company’s stock valued at $1,247,000 after purchasing an additional 6,200 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Phreesia by 5,462.3% during the 4th quarter. Russell Investments Group Ltd. now owns 3,838 shares of the company’s stock valued at $89,000 after buying an additional 3,769 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Phreesia during the fourth quarter worth approximately $242,000. M&T Bank Corp bought a new stake in shares of Phreesia in the fourth quarter worth $527,000. Finally, Private Advisor Group LLC acquired a new stake in Phreesia in the fourth quarter valued at $263,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.